TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
The latest update is out from Sandoz Group Ltd ( (CH:SDZ) ).
Sandoz has completed the acquisition of Just-Evotec Biologics EU SAS, enhancing its biosimilars development and manufacturing capabilities. This strategic move positions Sandoz to capitalize on the projected USD 300 billion biosimilars market opportunity over the next decade, reinforcing its leadership in the sector. The acquisition includes a site in Toulouse and a license to advanced continuous-manufacturing technology, which will improve efficiency and scalability. This expansion complements Sandoz’s ongoing investments in Slovenia, creating a robust biosimilars network across Europe without impacting its 2025 financial guidance.
The most recent analyst rating on (CH:SDZ) stock is a Hold with a CHF50.00 price target. To see the full list of analyst forecasts on Sandoz Group Ltd stock, see the CH:SDZ Stock Forecast page.
More about Sandoz Group Ltd
Sandoz is a global leader in affordable medicines, headquartered in Basel, Switzerland. The company focuses on pioneering access for patients, offering a portfolio of approximately 1,300 products that address a wide range of diseases. With a history dating back to 1886, Sandoz has been at the forefront of pharmaceutical breakthroughs, including the development of the world’s first biosimilar in 2006. In 2024, Sandoz recorded net sales of USD 10.4 billion.
YTD Price Performance: 58.10%
Average Trading Volume: 722,586
Technical Sentiment Signal: Buy
Current Market Cap: CHF25.39B
See more data about SDZ stock on TipRanks’ Stock Analysis page.